Combination of an agonistic anti-CD40 monoclonal antibody and the COX-2 inhibitor celecoxib induces anti-glioma effects by promotion of type-1 immunity in myeloid cells and T-cells.

Kosaka, Akemi; Ohkuri, Takayuki; Okada, Hideho

Kosaka, Akemi; Ohkuri, Takayuki; Okada, Hideho.

Affiliation

Kosaka A; Brain Tumor Program, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA.

Cancer Immunol Immunother ; 63(8): 847-57, 2014 Aug.

Article in En | MEDLINE | ID: mdl-24878890

Subject(s)

Antineoplastic Combined Chemotherapy Protocols/pharmacology; CD40 Antigens/agonists; Glioma/drug therapy; Glioma/immunology; Myeloid Cells/immunology; T-Lymphocytes, Cytotoxic/immunology; Animals; Antibodies, Monoclonal/administration & dosage; Antibodies, Monoclonal/immunology; CD40 Antigens/immunology; Celecoxib; Cyclooxygenase 2 Inhibitors/administration & dosage; Female; Mice; Mice, Inbred C57BL; Myeloid Cells/drug effects; Pyrazoles/administration & dosage; Rats; Sulfonamides/administration & dosage; Transfection

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: T-Lymphocytes, Cytotoxic / Antineoplastic Combined Chemotherapy Protocols / CD40 Antigens / Myeloid Cells / Glioma Type of study: Prognostic_studies Limits: Animals Language: En Year: 2014 Type: Article

Fulltext

XML

PubMed Links

Search on Google